Difference between revisions of "Irinotecan (Camptosar)"
Jump to navigation
Jump to search
m |
|||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Topoisomerase I inhibitor; derivative of camptothecin, which interferes with topoisomerase I's normal action of relieving torsional strain in DNA by creating reversible | + | Class/mechanism: Topoisomerase I inhibitor; derivative of camptothecin, which interferes with topoisomerase I's normal action of relieving torsional strain in DNA by creating reversible single-strand breaks. Irinotecan and its active metabolite SN-38 bind to the topoisomerase I & DNA complex and interfere with ligation of these single-strand breaks. Failure to repair these breaks eventually leads to double-strand DNA damage, which disrupts cell proliferation and leads to cell death.<ref name="insert">[http://labeling.pfizer.com/ShowLabeling.aspx?id=533 Irinotecan (Camptosar) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/irinotecan.pdf Irinotecan (Camptosar) package insert (locally hosted backup)]</ref> |
| − | single-strand breaks. Irinotecan and its active metabolite SN-38 bind to the topoisomerase | ||
| − | I & DNA complex and interfere with ligation of these single-strand breaks. | ||
<br>Route: IV | <br>Route: IV | ||
<br>Extravasation: [[irritant]] | <br>Extravasation: [[irritant]] | ||
| Line 12: | Line 10: | ||
*[[Anaplastic glioma]] | *[[Anaplastic glioma]] | ||
*[[Cervical cancer]] | *[[Cervical cancer]] | ||
| − | *[[ | + | *[[Colorectal cancer]] |
| + | **[[Rectal cancer]] | ||
*[[Esophageal cancer]] | *[[Esophageal cancer]] | ||
*[[Ewing sarcoma]] | *[[Ewing sarcoma]] | ||
| Line 50: | Line 49: | ||
[[Category:Anaplastic glioma medications]] | [[Category:Anaplastic glioma medications]] | ||
[[Category:Cervical cancer medications]] | [[Category:Cervical cancer medications]] | ||
| − | [[Category: | + | [[Category:Colorectal cancer medications]] |
[[Category:Esophageal cancer medications]] | [[Category:Esophageal cancer medications]] | ||
[[Category:Ewing sarcoma medications]] | [[Category:Ewing sarcoma medications]] | ||
| Line 58: | Line 57: | ||
[[Category:Non-small cell lung cancer medications]] | [[Category:Non-small cell lung cancer medications]] | ||
[[Category:Pancreatic cancer medications]] | [[Category:Pancreatic cancer medications]] | ||
| − | [[Category:Penile cancer medications]] | + | [[Category:Penile cancer medications]] |
| + | [[Category:Rectal cancer medications]] | ||
[[Category:Rhabdomyosarcoma medications]] | [[Category:Rhabdomyosarcoma medications]] | ||
[[Category:Small cell lung cancer medications]] | [[Category:Small cell lung cancer medications]] | ||
Revision as of 15:02, 30 April 2022
General information
Class/mechanism: Topoisomerase I inhibitor; derivative of camptothecin, which interferes with topoisomerase I's normal action of relieving torsional strain in DNA by creating reversible single-strand breaks. Irinotecan and its active metabolite SN-38 bind to the topoisomerase I & DNA complex and interfere with ligation of these single-strand breaks. Failure to repair these breaks eventually leads to double-strand DNA damage, which disrupts cell proliferation and leads to cell death.[1][2]
Route: IV
Extravasation: irritant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Carcinoma of unknown primary
- Anaplastic glioma
- Cervical cancer
- Colorectal cancer
- Esophageal cancer
- Ewing sarcoma
- Gastric cancer
- Glioblastoma
- Neuroblastoma
- Non-small cell lung cancer
- Pancreatic cancer
- Penile cancer
- Rhabdomyosarcoma
- Small cell lung cancer
Patient drug information
- Irinotecan (Camptosar) package insert[1]
- Irinotecan (Camptosar) patient drug information (Chemocare)[3]
- Irinotecan (Camptosar) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 6/14/1996: Initial accelerated approval for the treatment of patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following 5-FU-based therapy. (Based on Rothenberg et al. 1996, Pitot et al. 1997, Rougier et al. 1997, and Rothenberg et al. 1999)
- 10/22/1998: Converted to regular approval. (Based on V301 & V302)
- 4/20/2000: Indicated as a component of first-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic carcinoma of the colon or rectum. (Based on Douillard et al. 2000 & Saltz et al. 2000)
Also known as
- Code names: Camptothecin-11, CPT-11, U-101440E
- Brand names: Axinotecan, Biotecan, Biskam, Campto, Campostar, Camptosar, Elinatecan, Faultenocan, Irenax, Irinogen, Irinomedac, Irinotel, Irinotesin, Irnocam, Itoxaril, Linatecan, Onivyde, Satigene, Tecnotecan, Tekamen, Toptecin, Trinotecan, Winol
References
Categories:
- Drugs
- Intravenous medications
- Irritant
- Topoisomerase inhibitors
- Carcinoma of unknown primary medications
- Anaplastic glioma medications
- Cervical cancer medications
- Colorectal cancer medications
- Esophageal cancer medications
- Ewing sarcoma medications
- Gastric cancer medications
- Glioblastoma medications
- Neuroblastoma medications
- Non-small cell lung cancer medications
- Pancreatic cancer medications
- Penile cancer medications
- Rectal cancer medications
- Rhabdomyosarcoma medications
- Small cell lung cancer medications
- FDA approved in 1996
- WHO Essential Cancer Medicine